Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 358

1.

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update Summary.

Giordano SH, Temin S, Davidson NE.

J Oncol Pract. 2018 Jul 10:JOP1800290. doi: 10.1200/JOP.18.00290. [Epub ahead of print] No abstract available.

PMID:
29989839
2.

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.

Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Kirshner JJ, Krop IE, Levinson J, Modi S, Patt DA, Perlmutter J, Winer EP, Lin NU.

J Clin Oncol. 2018 Jun 25:JCO2018792713. doi: 10.1200/JCO.2018.79.2713. [Epub ahead of print]

PMID:
29939840
3.

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.

Giordano SH, Temin S, Chandarlapaty S, Crews JR, Esteva FJ, Kirshner JJ, Krop IE, Levinson J, Lin NU, Modi S, Patt DA, Perlmutter J, Ramakrishna N, Winer EP, Davidson NE.

J Clin Oncol. 2018 Jun 25:JCO2018792697. doi: 10.1200/JCO.2018.79.2697. [Epub ahead of print]

PMID:
29939838
4.

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group.

N Engl J Med. 2018 Jul 12;379(2):122-137. doi: 10.1056/NEJMoa1803164. Epub 2018 Jun 4.

5.

HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.

Cao C, Wu H, Vasilatos SN, Chandran U, Qin Y, Wan Y, Oesterreich S, Davidson NE, Huang Y.

Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31419. [Epub ahead of print]

PMID:
29633255
6.

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies.

Rakovitch E, Gray R, Baehner FL, Sutradhar R, Crager M, Gu S, Nofech-Mozes S, Badve SS, Hanna W, Hughes LL, Wood WC, Davidson NE, Paszat L, Shak S, Sparano JA, Solin LJ.

Breast Cancer Res Treat. 2018 Jun;169(2):359-369. doi: 10.1007/s10549-018-4693-2. Epub 2018 Jan 31.

7.

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.

Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, Morley S, Rosenzweig M, Gay LM, Goldberg ME, Suh J, Ali SM, Ross J, Leyland-Jones B, Young B, Williams C, Park B, Tsai M, Haley B, Peguero J, Callahan RD, Sachelarie I, Cho J, Atkinson JM, Bahreini A, Nagle AM, Puhalla SL, Watters RJ, Erdogan-Yildirim Z, Cao L, Oesterreich S, Mathew A, Lucas PC, Davidson NE, Brufsky AM, Frampton GM, Stephens PJ, Chmielecki J, Lee AV.

Ann Oncol. 2018 Apr 1;29(4):872-880. doi: 10.1093/annonc/mdy025.

8.

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A.

Lancet Oncol. 2017 Nov;18(11):e653-e706. doi: 10.1016/S1470-2045(17)30698-8. Epub 2017 Oct 31. Review.

PMID:
29208398
9.

Incident Cancer in Cancer Survivors-When Cancer Lurks in the Background.

Davidson NE.

JAMA Oncol. 2018 Jun 1;4(6):836-837. doi: 10.1001/jamaoncol.2017.4167. No abstract available.

PMID:
29167860
10.

Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.

Woodcock CC, Huang Y, Woodcock SR, Salvatore SR, Singh B, Golin-Bisello F, Davidson NE, Neumann CA, Freeman BA, Wendell SG.

J Biol Chem. 2018 Jan 26;293(4):1120-1137. doi: 10.1074/jbc.M117.814368. Epub 2017 Nov 20.

PMID:
29158255
11.

A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer.

Sparano JA, Gray R, Oktay MH, Entenberg D, Rohan T, Xue X, Donovan M, Peterson M, Shuber A, Hamilton DA, D'Alfonso T, Goldstein LJ, Gertler F, Davidson NE, Condeelis J, Jones J.

NPJ Breast Cancer. 2017 Nov 8;3:42. doi: 10.1038/s41523-017-0043-5. eCollection 2017.

12.

Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression.

Chen L, Vasilatos SN, Qin Y, Katz TA, Cao C, Wu H, Tasdemir N, Levine KM, Oesterreich S, Davidson NE, Huang Y.

Oncotarget. 2017 Jul 19;8(47):81737-81753. doi: 10.18632/oncotarget.19387. eCollection 2017 Oct 10.

13.

Searching for the IDEAL Duration of Adjuvant Endocrine Therapy.

Yung RL, Davidson NE.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx143. No abstract available.

PMID:
28922788
14.

Breast cancer: What lies beyond APHINITY for HER2-positive breast cancer?

Stanton SE, Davidson NE.

Nat Rev Clin Oncol. 2017 Dec;14(12):715-716. doi: 10.1038/nrclinonc.2017.125. Epub 2017 Aug 8. No abstract available.

PMID:
28786414
15.

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.

Bahreini A, Li Z, Wang P, Levine KM, Tasdemir N, Cao L, Weir HM, Puhalla SL, Davidson NE, Stern AM, Chu D, Park BH, Lee AV, Oesterreich S.

Breast Cancer Res. 2017 May 23;19(1):60. doi: 10.1186/s13058-017-0851-4.

16.

Practical Approach to Triple-Negative Breast Cancer.

Gadi VK, Davidson NE.

J Oncol Pract. 2017 May;13(5):293-300. doi: 10.1200/JOP.2017.022632. Review.

PMID:
28489980
17.

Optimal duration of trastuzumab for early HER2-positive breast cancer.

Specht JM, Davidson NE.

Lancet. 2017 Mar 25;389(10075):1167-1168. doi: 10.1016/S0140-6736(17)30322-7. Epub 2017 Feb 20. No abstract available.

PMID:
28215659
18.

Targeting tumorigenicity of breast cancer stem-like cells using combination epigenetic therapy: something old and something new.

Huang Y, Davidson NE.

J Thorac Dis. 2016 Nov;8(11):2971-2974. doi: 10.21037/jtd.2016.11.18. No abstract available.

19.

Disease Subtype-Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A.

Samanta SK, Sehrawat A, Kim SH, Hahm ER, Shuai Y, Roy R, Pore SK, Singh KB, Christner SM, Beumer JH, Davidson NE, Singh SV.

J Natl Cancer Inst. 2016 Dec 31;109(6). pii: djw293. doi: 10.1093/jnci/djw293. Print 2017 Jun.

20.

Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure.

Schneider BP, Shen F, Gardner L, Radovich M, Li L, Miller KD, Jiang G, Lai D, O'Neill A, Sparano JA, Davidson NE, Cameron D, Gradus-Pizlo I, Mastouri RA, Suter TM, Foroud T, Sledge GW Jr.

Clin Cancer Res. 2017 Jan 1;23(1):43-51. doi: 10.1158/1078-0432.CCR-16-0908. Epub 2016 Dec 19.

21.

Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.

Connolly RM, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater SA, Powers P, Wolff AC, Fetting JH, Brufsky A, Piekarz R, Ahuja N, Laird PW, Shen H, Weisenberger DJ, Cope L, Herman JG, Somlo G, Garcia AA, Jones PA, Baylin SB, Davidson NE, Zahnow CA, Stearns V.

Clin Cancer Res. 2017 Jun 1;23(11):2691-2701. doi: 10.1158/1078-0432.CCR-16-1729. Epub 2016 Dec 15.

22.

New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies.

Jankowitz RC, Oesterreich S, Lee AV, Davidson NE.

Clin Cancer Res. 2017 Mar 1;23(5):1126-1131. doi: 10.1158/1078-0432.CCR-16-0591. Epub 2016 Dec 15.

23.

Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.

Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Watters RJ, Thomas R, Leone JP, Lucas PC, Bhargava R, Hamilton RL, Chmielecki J, Puhalla SL, Davidson NE, Oesterreich S, Brufsky AM, Young L, Lee AV.

JAMA Oncol. 2017 May 1;3(5):666-671. doi: 10.1001/jamaoncol.2016.5630.

24.

Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer.

Gyanchandani R, Lin Y, Lin HM, Cooper K, Normolle DP, Brufsky A, Fastuca M, Crosson W, Oesterreich S, Davidson NE, Bhargava R, Dabbs DJ, Lee AV.

Clin Cancer Res. 2016 Nov 1;22(21):5362-5369. Epub 2016 May 16.

25.

AACR Cancer Progress Report 2016.

Davidson NE, Armstrong SA, Coussens LM, Cruz-Correa MR, DeBerardinis RJ, Doroshow JH, Foti M, Hwu P, Kensler TW, Morrow M, Mulligan CG, Pao W, Platz EA, Smith TJ, Willman CL.

Clin Cancer Res. 2016 Oct 1;22(19 Supplement):S1-S137. No abstract available.

26.

WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.

Sikora MJ, Jacobsen BM, Levine K, Chen J, Davidson NE, Lee AV, Alexander CM, Oesterreich S.

Breast Cancer Res. 2016 Sep 20;18(1):92. doi: 10.1186/s13058-016-0748-7.

27.

Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?

Brufsky AM, Davidson NE.

Clin Cancer Res. 2016 Oct 15;22(20):4963-4965. Epub 2016 Aug 12.

28.

"Take two"? The role of second opinions for breast biopsy specimens.

Bhargava R, Davidson NE.

BMJ. 2016 Jun 23;353:i3256. doi: 10.1136/bmj.i3256. No abstract available.

PMID:
27339037
29.

Breast cancer: The 21-gene recurrence score - biology remains at the forefront.

Puhalla SL, Davidson NE.

Nat Rev Clin Oncol. 2016 Aug;13(8):470-2. doi: 10.1038/nrclinonc.2016.98. Epub 2016 Jun 14. No abstract available.

PMID:
27296295
30.

Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer.

Azim HA Jr, Davidson NE, Ruddy KJ.

Am Soc Clin Oncol Educ Book. 2016;35:23-32. doi: 10.14694/EDBK_159069.

31.

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Vose JM, Schilsky RL.

J Clin Oncol. 2016 Aug 20;34(24):2925-34. doi: 10.1200/JCO.2016.68.2518. Epub 2016 May 31. No abstract available.

PMID:
27247218
32.

Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression.

Cao C, Vasilatos SN, Bhargava R, Fine JL, Oesterreich S, Davidson NE, Huang Y.

Oncogene. 2017 Jan 5;36(1):133-145. doi: 10.1038/onc.2016.186. Epub 2016 May 23.

33.

Serendipity and purpose.

Davidson NE.

Endocr Relat Cancer. 2016 May;23(5):P1-3. doi: 10.1530/ERC-16-0149. Epub 2016 Apr 8. No abstract available.

34.

Reply to C. Shah et al.

Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE.

J Clin Oncol. 2016 May 20;34(15):1824-5. doi: 10.1200/JCO.2016.66.4714. Epub 2016 Mar 21. No abstract available.

PMID:
27001578
35.

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.

Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ.

J Clin Oncol. 2016 May 10;34(14):1689-701. doi: 10.1200/JCO.2015.65.9573. Epub 2016 Feb 16. Review.

PMID:
26884586
36.

Conquering Metastatic Breast Cancer.

Davidson NE.

J Oncol Pract. 2016 Jan;12(1):11-2. doi: 10.1200/JOP.2015.009167. No abstract available.

37.

Transforming Cancer Prevention through Precision Medicine and Immune-oncology.

Kensler TW, Spira A, Garber JE, Szabo E, Lee JJ, Dong Z, Dannenberg AJ, Hait WN, Blackburn E, Davidson NE, Foti M, Lippman SM.

Cancer Prev Res (Phila). 2016 Jan;9(1):2-10. doi: 10.1158/1940-6207.CAPR-15-0406.

38.

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer.

Dowsett M, Lønning PE, Davidson NE.

J Clin Oncol. 2016 May 10;34(14):1580-3. doi: 10.1200/JCO.2015.62.3728. Epub 2016 Jan 4. No abstract available.

PMID:
26729430
39.

Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198).

Schneider BP, O'Neill A, Shen F, Sledge GW, Thor AD, Kahanic SP, Zander PJ, Davidson NE.

Br J Cancer. 2015 Dec 22;113(12):1651-7. doi: 10.1038/bjc.2015.405. Epub 2015 Dec 1.

40.

Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.

Wang P, Bahreini A, Gyanchandani R, Lucas PC, Hartmaier RJ, Watters RJ, Jonnalagadda AR, Trejo Bittar HE, Berg A, Hamilton RL, Kurland BF, Weiss KR, Mathew A, Leone JP, Davidson NE, Nikiforova MN, Brufsky AM, Ambros TF, Stern AM, Puhalla SL, Lee AV, Oesterreich S.

Clin Cancer Res. 2016 Mar 1;22(5):1130-7. doi: 10.1158/1078-0432.CCR-15-1534. Epub 2015 Oct 23.

41.

The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.

Perez EA, Baehner FL, Butler SM, Thompson EA, Dueck AC, Jamshidian F, Cherbavaz D, Yoshizawa C, Shak S, Kaufman PA, Davidson NE, Gralow J, Asmann YW, Ballman KV.

Breast Cancer Res. 2015 Oct 1;17(1):133. doi: 10.1186/s13058-015-0643-7.

42.

Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.

Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE.

J Clin Oncol. 2015 Nov 20;33(33):3938-44. doi: 10.1200/JCO.2015.60.8588. Epub 2015 Sep 14.

43.

Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a Parity-Induced Hypermethylation of Igf1r That Persists Long after Parturition.

Katz TA, Liao SG, Palmieri VJ, Dearth RK, Pathiraja TN, Huo Z, Shaw P, Small S, Davidson NE, Peters DG, Tseng GC, Oesterreich S, Lee AV.

Cancer Prev Res (Phila). 2015 Oct;8(10):1000-9. doi: 10.1158/1940-6207.CAPR-15-0178. Epub 2015 Aug 19.

44.

Developing in vitro models of human ductal carcinoma in situ from primary tissue explants.

Brown DD, Dabbs DJ, Lee AV, McGuire KP, Ahrendt GM, Bhargava R, Davidson NE, Brufsky AM, Johnson RR, Oesterreich S, McAuliffe PF.

Breast Cancer Res Treat. 2015 Sep;153(2):311-21. doi: 10.1007/s10549-015-3551-8. Epub 2015 Aug 18.

PMID:
26283301
45.

Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.

Mathew A, Davidson NE.

Breast. 2015 Nov;24 Suppl 2:S120-5. doi: 10.1016/j.breast.2015.07.027. Review.

PMID:
26255743
46.

The molecular landscape of premenopausal breast cancer.

Liao S, Hartmaier RJ, McGuire KP, Puhalla SL, Luthra S, Chandran UR, Ma T, Bhargava R, Modugno F, Davidson NE, Benz S, Lee AV, Tseng GC, Oesterreich S.

Breast Cancer Res. 2015 Aug 7;17:104. doi: 10.1186/s13058-015-0618-8.

47.

Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.

Schneider BP, Li L, Radovich M, Shen F, Miller KD, Flockhart DA, Jiang G, Vance G, Gardner L, Vatta M, Bai S, Lai D, Koller D, Zhao F, O'Neill A, Smith ML, Railey E, White C, Partridge A, Sparano J, Davidson NE, Foroud T, Sledge GW Jr.

Clin Cancer Res. 2015 Nov 15;21(22):5082-5091. doi: 10.1158/1078-0432.CCR-15-0586. Epub 2015 Jul 2.

48.

A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer.

Nayak SR, Harrington E, Boone D, Hartmaier R, Chen J, Pathiraja TN, Cooper KL, Fine JL, Sanfilippo J, Davidson NE, Lee AV, Dabbs D, Oesterreich S.

Horm Cancer. 2015 Dec;6(5-6):214-24. doi: 10.1007/s12672-015-0230-5. Epub 2015 Jun 26.

49.

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.

Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Schilsky RL, American Society of Clinical Oncology.

J Clin Oncol. 2015 Aug 10;33(23):2563-77. doi: 10.1200/JCO.2015.61.6706. Epub 2015 Jun 22. No abstract available.

50.

Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.

Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE.

J Clin Oncol. 2015 Jul 20;33(21):2353-60. doi: 10.1200/JCO.2015.60.9271. Epub 2015 Jun 15.

Supplemental Content

Loading ...
Support Center